Ventyx Biosciences Inc (VTYX)

$3.60 +0.07 (1.98%)
Market Cap 256.71M
Revenue (ttm) 0.00
Net Income (ttm) -135.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,921,500
Avg Vol 903,188
Day's Range N/A - N/A
Shares Out 71.31M
Stochastic %K 75%
Beta 1.01
Analysts Strong Sell
Price Target $11.50

Company Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like recept...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 593 4832
Address:
12790 El Camino Real, Suite 200, San Diego, United States
highnihilism
highnihilism Oct. 5 at 8:35 PM
$VTYX Ventyx Biosciences (option volume 10-03-25) 3.60 +2.0% | 59 trades | total $54K | 90-day avg $31.2K × 1.73 call $53.9K | put $50 | 100% single-leg, 0% multi-leg, 0% contingent
0 · Reply
biospeculator
biospeculator Oct. 5 at 6:35 PM
$VTYX Posting on a rainy day in South Florida and running technical analysis on VTYX. It's simple. A close for three days above $4 and we run to $12-$14. With multiple trial results due in next few months, that is exactly what I am expecting. I am long. GLTA
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 5 at 7:44 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $VTYX Current Share Price: $3.60 Contracts: $VTYX March 20, 2026 $5 Calls Scale in: $0.91- $1.11 Scale out: $1.42-$1.82 Can Easily Capture: 60% ROI Blended DTE: 168 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
msp3501
msp3501 Oct. 3 at 1:51 PM
$VTYX
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 2 at 4:47 PM
$VTYX just reverted 3% higher to -2% (~2Mv) a moment ago, 10/17 options, follow for more volatility.
0 · Reply
elmono
elmono Oct. 2 at 3:10 PM
$VTYX on the other hand: feels like it is shorted today…maybe I shouldn’t post positively on tickers anymore…🤷‍♂️😂😂😂.
1 · Reply
elmono
elmono Oct. 2 at 2:55 PM
$VTYX UC hidden gem…..just like $PALI, $ABVX ahead….but expensive
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 2 at 2:27 PM
$VTYX Current Stock Price: $3.60 Contracts to trade: $2.0 VTYX Oct 17 2025 Call Entry: $1.50 Exit: $2.70 ROI: 80% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Oct. 2 at 1:04 PM
$VTYX
0 · Reply
Elevate1
Elevate1 Oct. 2 at 12:56 PM
$VTYX obviously the data must be good!
0 · Reply
Latest News on VTYX
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Aug 27, 2025, 7:02 AM EDT - 5 weeks ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 4 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

May 8, 2025, 4:01 PM EDT - 5 months ago

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Apr 1, 2025, 7:00 AM EDT - 6 months ago

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Feb 27, 2025, 4:05 PM EST - 7 months ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Feb 18, 2025, 8:00 AM EST - 8 months ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 8 months ago

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Jan 14, 2025, 8:00 AM EST - 9 months ago

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Nov 4, 2024, 10:32 AM EST - 11 months ago

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

Sep 23, 2024, 11:13 AM EDT - 1 year ago

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

SNY

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Ventyx Biosciences Announces Departure of Chief Financial Officer

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Departure of Chief Financial Officer

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Jul 29, 2024, 2:31 PM EDT - 1 year ago

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

Jul 29, 2024, 11:03 AM EDT - 1 year ago

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

Jun 24, 2024, 6:00 AM EDT - 1 year ago

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

Jun 21, 2024, 4:15 PM EDT - 1 year ago

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

Jun 20, 2024, 7:20 AM EDT - 1 year ago

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

Jun 19, 2024, 4:20 PM EDT - 1 year ago

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

Jun 18, 2024, 3:42 PM EDT - 1 year ago

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 17, 2024, 6:32 AM EDT - 1 year ago

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 4:06 PM EDT - 1 year ago

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

Jun 13, 2024, 7:13 AM EDT - 1 year ago

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

Jun 12, 2024, 4:04 PM EDT - 1 year ago

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 11, 2024, 3:37 PM EDT - 1 year ago

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

Jun 11, 2024, 6:41 AM EDT - 1 year ago

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 8, 2024, 5:24 AM EDT - 1 year ago

VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Jun 5, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

May 16, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript

May 11, 2024, 1:58 PM EDT - 1 year ago

Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

May 2, 2024, 4:05 PM EDT - 1 year ago

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

Apr 30, 2024, 8:00 AM EDT - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

Apr 28, 2024, 7:00 PM EDT - 1 year ago

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Apr 28, 2024, 1:00 PM EDT - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

highnihilism
highnihilism Oct. 5 at 8:35 PM
$VTYX Ventyx Biosciences (option volume 10-03-25) 3.60 +2.0% | 59 trades | total $54K | 90-day avg $31.2K × 1.73 call $53.9K | put $50 | 100% single-leg, 0% multi-leg, 0% contingent
0 · Reply
biospeculator
biospeculator Oct. 5 at 6:35 PM
$VTYX Posting on a rainy day in South Florida and running technical analysis on VTYX. It's simple. A close for three days above $4 and we run to $12-$14. With multiple trial results due in next few months, that is exactly what I am expecting. I am long. GLTA
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 5 at 7:44 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $VTYX Current Share Price: $3.60 Contracts: $VTYX March 20, 2026 $5 Calls Scale in: $0.91- $1.11 Scale out: $1.42-$1.82 Can Easily Capture: 60% ROI Blended DTE: 168 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
msp3501
msp3501 Oct. 3 at 1:51 PM
$VTYX
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 2 at 4:47 PM
$VTYX just reverted 3% higher to -2% (~2Mv) a moment ago, 10/17 options, follow for more volatility.
0 · Reply
elmono
elmono Oct. 2 at 3:10 PM
$VTYX on the other hand: feels like it is shorted today…maybe I shouldn’t post positively on tickers anymore…🤷‍♂️😂😂😂.
1 · Reply
elmono
elmono Oct. 2 at 2:55 PM
$VTYX UC hidden gem…..just like $PALI, $ABVX ahead….but expensive
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 2 at 2:27 PM
$VTYX Current Stock Price: $3.60 Contracts to trade: $2.0 VTYX Oct 17 2025 Call Entry: $1.50 Exit: $2.70 ROI: 80% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Oct. 2 at 1:04 PM
$VTYX
0 · Reply
Elevate1
Elevate1 Oct. 2 at 12:56 PM
$VTYX obviously the data must be good!
0 · Reply
StockScanners
StockScanners Oct. 2 at 12:46 AM
$VTYX reached to 3.92, lets go team
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Oct. 1 at 9:47 PM
$NVTS $VTYX 👀
0 · Reply
Gemini367
Gemini367 Oct. 1 at 6:46 PM
$VTYX $4 on deck. Potential news catalyst. Strong increase in daily volume without any news. I am still holding my position. Buyout potential. Good luck.
1 · Reply
DARKP00L
DARKP00L Oct. 1 at 4:59 PM
$VTYX 12:52 on Oct. 01 2025 Ventyx Biosciences shares are trading higher after Clear Street initiated coverage on the stock with a Buy rating and announced a $11 price target. #tradeideas
0 · Reply
Elevate1
Elevate1 Oct. 1 at 4:16 PM
$VTYX
0 · Reply
Joe_088
Joe_088 Oct. 1 at 3:49 PM
$ATOS $MBOT $VTYX
1 · Reply
Elevate1
Elevate1 Oct. 1 at 3:33 PM
$VTYX
0 · Reply
Elevate1
Elevate1 Oct. 1 at 3:33 PM
$VTYX They said Data coming out which we know the individual products work. This oral semiglutide plus 3232 will be a monster and force the bidding war I have been predicting. If ode paid $7.3 for a weaker product family tgen Sanofi forced by NVO will have to pay much more. This will be a hypersonic move if so! I am long and willing to buy or sell at will
0 · Reply
Kevin73ca
Kevin73ca Oct. 1 at 3:10 PM
$AIHS $AKAN $APLT $PALI $VTYX
0 · Reply
PaulLaurent
PaulLaurent Oct. 1 at 3:07 PM
📊🔥 Top Gainers Update 💰🚨11:03:am $PALI $AIHS $AKAN $APLT $VTYX
0 · Reply
DaBullRunner
DaBullRunner Oct. 1 at 3:07 PM
$VTYX there it goes….. ICU is going to make a big run soon 🚨🚨🚨🚨🚨 Here’s why👇
0 · Reply
BinaryLogic
BinaryLogic Oct. 1 at 3:00 PM
$VTYX The stock/Company has not even received the attention of the broader market yet. This is a strong Company financially (IMO), undervalued with a dynamic product portfolio and multiple catalysts in Q4-2025 into 2026. It is a possible buyout/acquisition target (IMO) still with excellent upside intermediate/long-term on pipeline success/progress.
0 · Reply